Prime Therapeutics

This October, Prime Therapeutics is attending the SIIA (Self-Insurance Institute of America) National Conference in Phoenix, Arizona. We are thrilled to join thousands of industry leaders to gain insights from experts, forge lasting connections and explore the latest solutions in the marketplace. Meet us there at booth 119! More events: https://bit.ly/453kj6f

Prime’s Quarterly Drug Pipeline delivers the latest insights on drugs under review by the United States (U.S.) Food and Drug administration (FDA) or in late-stage development. Our report features deep dives on select drugs that are awaiting FDA approval, including rare conditions — like Hunter syndrome — spinal muscular atrophy and Wiskott-Aldrich syndrome. It also highlights potential new treatments for multiple sclerosis, immunoglobulin A (IgA) nephropathy and Cushing syndrome. You can also read about new indications for GLP-1 agents, including metabolic dysfunction-associated steatohepatitis (MASH) and a potential first oral GLP-1 for weight management. Keep reading: https://bit.ly/41n9w5E

Pat Gleason, PharmD, BCPS, FCCP, FAMCP shares insights from Prime’s third year of real-world GLP-1 data. The findings show a continued decline in therapy persistence over time, with slightly higher rates among individuals using high-potency GLP-1 drugs. Read the full analysis: https://bit.ly/3HZw3yF

“Providing a flexible work environment that thoughtfully encourages connection, collaboration and empowerment helps Prime's teams feel supported in their careers and in life," says Erin Feigal, chief human resources officer, in a recent interview with the St. Paul Pioneer Press. Learn how Prime's Hub + Home® model balances flexibility with the need for in-person collaboration, making Prime one of the best companies for remote work. Keep reading: https://bit.ly/47aIMZY

We’re proud to be recognized as a top scorer on the Disability:IN for our commitment to disability inclusion in the workplace. At Prime, we believe accessibility and equity are essential to building a stronger, more inclusive culture. Learn more about this recognition and our ongoing efforts: https://bit.ly/4mlK88E

We want your input! ⤵️ Our experts Brian MacDonald, Yuqian Liu and IPD Analytics Jeffrey Casberg will spotlight pipeline trends at Specialty Summit, Sept. 15–17 in New York City. With so many specialty drugs in development, we aim to highlight the ones that matter most to you.

Prime is heading to the Medicaid Enterprise Systems Conference (MESC) next week! Event link: https://bit.ly/453kj6f

Check out the latest Prime Therapeutics report for info on Duchenne muscular dystrophy (DMD), a rare genetic condition that progressively worsens, causing weakness and muscle wasting. You’ll learn about the symptoms to watch for and strategies for getting patients the appropriate treatment at the time they need it. Access the full report: https://bit.ly/3ISNWzP

At Prime, our people are the heart of everything we do. In this video, Fayka El-Sarraf shares how Prime empowers her to bring her best self to work and beyond. We're proud to support our team every step of the way — from professional growth to personal well-being. Explore how you can reimagine pharmacy: https://bit.ly/40LlANg

Prime’s latest Quarterly Drug Approvals offers a strategic look at therapies approaching FDA decisions and the clinical developments shaping the second half of 2025. From early-stage innovation to market readiness, the July pipeline is a valuable tool for navigating today’s complex drug landscape. Take a moment to explore high-impact therapies. Keep reading: https://bit.ly/41n9w5E